{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\ud83c\udfaf Lower. Further. Better: The New LDL Frontier","description":"The New England Journal of Medicine has now given us randomized trial evidence for a question long guided more by extrapolation than by direct proof: in patients with established atherosclerotic cardiovascular disease, targeting LDL cholesterol to &amp;lt;55 mg\/dL beat a target of &amp;lt;70 mg\/dL over 3 years. In Ez-PAVE, the primary end point occurred in 6.6% vs 9.7%, with a hazard ratio of 0.67, supporting a more intensive LDL strategy for secondary prevention. &amp;nbsp; Elegant trial, practical message: when risk is high, lower may truly be better. \ud83e\udec0\ud83d\udcc9\ud83c\udfaf Journal: New England Journal of Medicine. ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40705795\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/200367470"}